Voluntary nationwide recall: Duloxetine (Towa – October)

Dec. 2024Pharmacy Updates

Towa Pharmaceutical is recalling one lot, lot 220128, of Duloxetine Delayed-Release Capsules, USP, 20 mg. Duloxetine is used to treat anxiety, depression, and certain types of nerve pain.

This drug is being recalled because it contained an impurity called N-nitroso-duloxetine. According to the FDA, nitrosamine impurities may increase the risk of cancer if people are exposed to them above acceptable levels and over long periods of time. Additionally, the FDA added that someone who is taking a drug that contains nitrosamines at or below the acceptable daily intake limits every day for several years is not expected to have an increased risk of cancer.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA report and website below. If you have an affected lot of Duloxetine, The FDA advises that you should stop using the product and return it to the place of purchase or throw it away.

As of Oct. 23, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.

Recent Announcements

PA DOH Antibiotic Stewardship Resources

Order antibiotic stewardship resources at no cost
Jun. 2026Important Notices

Medical device correction: Omnipod (Insulet – May 2026)

Insulet Corporation Inc. has announced a medical device correction for certain Omnipod Pods. These pods are wearable devices that are used to deliver insulin.
Jun. 2026Pharmacy Updates

Clinical documentation required for medical policy prior authorizations

As you know, UPMC Health Plan requires certain clinical documentation/notes in support of a request for prior authorization for the listed procedures below in accordance with its established policies and procedures, in addition to CMS requirements that medical record documentation must support the medical necessity of the services requested.
Jun. 2026Important Notices